MISSISSAUGA, Ontario, June 29, 2011 /PRNewswire/ — CardioGenics
Holdings Inc. (CGNH.OB) announced today that the United States
Patent & Trademark Office (USPTO) has notified the company that
its patent application has been granted (issued patent #
7,964,415). This patent covers CardioGenics Inc.’s
proprietary signal amplification technology, which is a key
component of the core technology for CardioGenics’ Ultra-Sensitive
QL Care™ Analyzer. CardioGenics’ unique methodology for
signal amplification enables a decrease in the amount of binding
reagents used in immunoassay diagnostic tests, such as those to be
performed on the QL Care™ Analyzer, which, in turn, results
in improved signal-to-noise ratio thereby increasing testing
sensitivity.
“We are very pleased that the USPTO has recognized the unique
nature of CardioGenics’ signal amplification technology,” said Dr.
Yahia Gawad, CEO of CardioGenics. “This patent is an important
addition to our patent portfolio since it addresses a key component
of the technology that permits the ultra-sensitive performance of
our QL Care™ Analyzer,” continued Dr. Gawad.
About CardioGenics Holdings Inc.
Through its operating subsidiaries, the Company develops
ultra-sensitive analyzers and other products targeting the
immunoassay segment of the Point-Of-Care IVD testing market. It has
developed the QL Care™ Analyzer, a proprietary and
ultra-sensitive Point-Of-Care immuno-analyzer, which will run a
number of diagnostic tests under development, the first of which
will be a series of cardiovascular diagnostic tests. As part of its
core proprietary technology, the Company has also developed a
proprietary method for silver coating paramagnetic microspheres (a
fundamental platform component of immunoassay equipment), which
improve instrument sensitivity to light. The Company’s proprietary
microspheres technology and SAVAsphere™ magnetic beads
are developed
‘/>”/>
